Form 4: Inotiv CEO Robert Leasure Jr. Receives Stock and Option Grants

Inotiv's CEO, Robert Leasure Jr., was granted restricted stock units and stock options on March 14, 2025, according to a recent SEC filing.

Summary

• Robert Leasure Jr., CEO of Inotiv, Inc., received a grant of 429,730 restricted stock units on March 14, 2025, which will vest in full on March 14, 2027, contingent upon continued employment.
• Leasure also received a grant of stock options for 429,730 shares with an exercise price of $2.79, vesting over three years beginning on the first anniversary of the grant date.
• Following these transactions, Leasure directly owns 1,386,322 shares of Inotiv common stock.
• He also indirectly owns 105,000 shares through an entity where he is the majority security holder, but he disclaims beneficial ownership except to the extent of his pecuniary interest.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The grant of equity compensation is a standard practice and suggests confidence in the CEO's ability to drive future growth, but it also represents potential dilution for existing shareholders.

Positives

• The grant of restricted stock units and stock options aligns the CEO's interests with those of the shareholders, incentivizing him to improve the company's performance.
• The vesting schedules for both the restricted stock units and stock options encourage long-term commitment from the CEO.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules of the granted securities.

Industry Context

Stock and option grants are a common form of executive compensation in the biotech and pharmaceutical services industry, used to attract and retain talent and align management's interests with shareholder value.

Comparison to Industry Standards

• Executive compensation packages, including stock options and restricted stock units, are standard practice among publicly traded companies, particularly in the biotech and pharmaceutical services sectors.
• Companies like Charles River Laboratories and Envigo (now part of Inotiv) also utilize similar equity-based compensation to incentivize their executives.
• The vesting schedules and grant sizes are generally benchmarked against peer companies to ensure competitiveness and alignment with performance goals.

Stakeholder Impact

• Shareholders may experience potential dilution due to the issuance of new shares upon the vesting of restricted stock units and exercise of stock options.
• Employees may view the CEO's equity compensation as a positive sign of the company's commitment to its leadership.
• The grants incentivize the CEO to focus on long-term value creation, which could benefit all stakeholders.

Key Dates